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Abstract
Background: There is growing evidence of an association between low vitamin D and HIV disease progression; however, no
prospective studies have been conducted among adults receiving antiretroviral therapy (ART) in sub-Saharan Africa.
Methods: Serum 25-hydroxyvitamin D (25(OH)D) levels were assessed at ART initiation for a randomly selected cohort of
HIV-infected adults enrolled in a trial of multivitamins (not including vitamin D) in Tanzania during 2006–2010. Participants
were prospectively followed at monthly clinic visits for a median of 20.6 months. CD4 T-cell measurements were obtained
every 4 months. Proportional hazard models were utilized for mortality analyses while generalized estimating equations
were used for CD4 T-cell counts.
Results: Serum 25(OH)D was measured in 1103 adults 9.2% were classified as vitamin D deficient (,20 ng/ml), 43.6%
insufficient (20–30 ng/mL), and 47.2% as sufficient (.30 ng/mL). After multivariate adjustment, vitamin D deficiency was
significantly associated with increased mortality as compared to vitamin D sufficiency (HR: 2.00; 95% CI: 1.19–3.37;
p=0.009), whereas no significant association was found for vitamin D insufficiency (HR: 1.24; 95% CI: 0.87–1.78; p=0.24). No
effect modification by ART regimen or change in the associations over time was detected. Vitamin D status was not
associated with change in CD4 T-cell count after ART initiation.
Conclusions: Deficient vitamin D levels may lead to increased mortality in individuals receiving ART and this relationship
does not appear to be due to impaired CD4 T-cell reconstitution. Randomized controlled trials are needed to determine the
safety and efficacy of vitamin D supplementation for individuals receiving ART.
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Introduction
In 2002 only 2% of HIV-infected individuals eligible for
antiretroviral therapy (ART) in sub-Saharan were receiving
treatment, while by the end of 2010 this proportion increased to
49% with over 5 million people receiving ART [1]. Despite
successes in expanding treatment coverage, individuals initiating
ART in sub-Saharan Africa experience high mortality rates and
interventions are needed to prolong and improve quality of life
[2,3].
Vitamin D is a potent immunomodulator with effects on both
adaptive and innate immune responses [4,5]. Vitamin D may play
a particularly strong role in control of intracellular pathogens by
enhancing cell-mediated immunity, production of antimicrobial
peptides, and phagocytic activity of macrophages [6–9]. As a result,
HIV-infected individuals with adequate levels of vitamin D may
better control HIV or opportunistic infections compared to
deficient individuals [10]. Further, vitamin D has effects on
multiple organ systems and HIV-infected individuals with low
levels of vitamin D could experience increased complications of
ART including: cardiovascular disease, insulin resistance, and
renal impairment [11–13].
Three previous cohorts have investigated the association of
vitamin D status and HIV mortality; however, each of these
studies has methodological or generalizability limitations. The first
small study conducted in Norway before introduction of ART
found that HIV-infected individuals with low 1, 25(OH)2D (active
form of vitamin D) had significantly decreased survival time
compared to individuals with normal levels [14]. However, serum
1,25(OH)2D is considered a sub-optimal measure of vitamin D
status and serum 25-hydroxyvitamin D (25(OH)D) is the only
vitamin D metabolite that should be employed to assess vitamin D
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women in Tanzania not receiving ART, found women in the
highest quintile of 25(OH)D, had 42% lower risk of all-cause
mortality as compared to those in the lowest quintile [16]. Low
vitamin D was also associated with wasting, anemia, and incidence
of acute upper respiratory infections in these women [17,18].
Nevertheless, these results may not be generalizable to men and
non-pregnant women receiving ART since pregnancy and
antiretroviral drugs can interact with vitamin D metabolism and
the role of vitamin D may be altered during immune re-
constitution [19,20]. The third cohort study consisted of adults
in 31 European countries, Israel, and Argentina who were mostly
receiving ART and similarly found adults in the highest tertile of
25(OH)D had a 0.56 times the rate of mortality compared to
individuals in the lowest tertile [21]. However, these finding may
not be generalizable to individuals receiving ART in resource-
limited countries. Individuals receiving ART in developing
countries initiate at significantly lower CD4 T-cell counts and
have higher risk of comorbid infections, which may modify the
impact of vitamin D on mortality [22].
To date no longitudinal studies of vitamin D and HIV disease
progression have been conducted among adults receiving ART in
sub-Saharan Africa or for men and non-pregnant women in
a resource-limited setting. Examining the relationship between
vitamin D and HIV disease progression in this population is
essential given over one million adults initiated ART in sub-
Saharan Africa in 2010 and coverage is rapidly expanding [1].
Furthermore, no studies have investigated the impact of vitamin D
on change in CD4 T-cell count in HIV-infected individuals
receiving ART in a resource-limited setting where individuals start
ART at low CD4 T-cell counts, which will give valuable insight to
the mechanism of vitamin D on mortality. Here we present
a prospective cohort study of Tanzanian adults initiating ART to
address these knowledge gaps.
Materials and Methods
Study Population
This prospective cohort study consisted of randomly selected
sample of HIV-infected men and women initiating ART enrolled
in a double-blind, randomized controlled trial assessing the effect
of daily oral supplements of vitamins B-complex, C, and E at high
versus standard levels of the recommended dietary allowance
(RDA) on HIV disease progression conducted in Dar es Salaam,
Tanzania during 2006–2010. Participants were recruited from 7
HIV care and treatment centres in Dar es Salaam with the support
of the National AIDS Control Program and the President’s
Emergency Plan for AIDS Relief program and in collaboration
with the Harvard School of Public Health, Muhimbili University
of Health and Allied Sciences, and the City of Dar es Salaam
Regional Office of Health.
Individuals were eligible for the study if they were aged $18
years, HIV-infected, initiating ART at enrollment, and intended
to stay in the city of Dar es Salaam for at least 2 years. Women
who were pregnant or lactating were excluded from the study. At
the time of the study, patients with World Health Organization
(WHO) HIV disease stage IV, CD4 T-cell count ,200 cells/ mL,
or with WHO HIV stage III disease and CD4 T-cell count ,350
cells/ mL were initiated on HAART [23]. First-line drug
combinations included stavudine (d4T), lamivudine (3TC), nevir-
apine (NVP), zidovudine (AZT), and efavirenz (EFV). AZT was
substituted for d4T for individuals with peripheral neuropathy or
who could not tolerate d4T. EFV was substituted for NVP in
patients who could not tolerate NVP. Therefore four different
ART regimens were used in trial: (i) d4T - 3TC - NVP, (ii) d4T -
3TC - EFV, (iii) AZT - 3TC - NVP, (iv) AZT - 3TC - EFV. Co-
trimoxazole prophylaxis was provided when CD4 T-cell counts
were ,200 cells/ mL, and treatment for all opportunistic infection
was provided according to the national and WHO guidelines.
Baseline Covariate Assessment
At enrollment, a full clinical examination was conducted and
a structured interview was completed to collect information on
demographic characteristics. Season of the baseline visit catego-
rized by long rain (December-March), harvest (April-May), post-
harvest (June-August), and short rain (September-November).
Study physicians performed a complete medical examination and
assessed HIV disease stage in accordance with the WHO
guidelines, and collected blood specimens. Absolute CD4 T-cell
count (FACSCalibur flow cytometer, Becton Dickinson, San Jose,
CA) and complete blood count (AcT5 Diff AL analyzer, Beckman
Coulter, Miami, FL) were also determined. Height/weight
measurements were obtained by trained research assistants using
standardized procedures and calibrated instruments.
Vitamin D Assessment
Blood samples were obtained from study participants at baseline
and plasma was stored at or below 270uC. 25(OH)D was
quantified by high performance liquid chromatography tandem
mass spectrometry (HPLC-MS/MS) using an API-5000 (AB Sciex,
Foster City, CA) at Children’s Hospital Boston [24]. Serum
samples were first extracted and ‘cleaned up’ using the Aria-TLX-
2 (Thermo Fisher Scientific, Waltham, MA) after which 50 mL was
mixed with acetonitrile containing internal standard of 25-
hydroxyviatmin d6D3. Samples were then centrifuged and
50 mL of the supernatant was injected into the Aria-TLX-2,
passed through a Cyclone-P column (Thermo Fisher Scientific),
and then eluted through a Kinetex C column (Phenomenex,
Torrance, CA). The eluate was injected into the API-5000 for
atmospheric pressure chemical ionization and passed through the
triple quadrupole mass spectrometer for detection and quantified
measurements. The assay is linear up to 100 ng/mL, and sensitive
to 1 ng/mL. Day-to-day precision (%CV) at various levels of
25(OH)D ranged from 5.6% to 8.5%.
Outcome Assessment
Participants were followed at monthly clinic visits where
physicians performed a clinical evaluation and a nurse assessed
self-reported symptoms and HIV-related complications since the
last visit. Absolute CD4 T-cell count was determined every 4
months. Participants who missed a clinic visit were followed at
home where relatives or neighbors were asked about vital status of
the participant.
Statistical Methods
We examined risk factors for low vitamin D status (25(OH)D
,30 ng/mL) at ART initiation using binomial regression models
in order to obtain risk ratio estimates [25,26]. In a few instances,
the models did not converge and log-Poisson models, which
provide consistent but not fully efficient estimates of the relative
risk and its confidence intervals were used [27]. Variables included
in this analysis included: sex, age, season, body mass index (BMI),
WHO HIV disease stage, baseline CD4 T-cell count, and
hemoglobin levels.
The relationship of vitamin D levels at ART initiation and
mortality was investigated using proportional hazard models [28].
There is not absolute consensus on the ideal 25(OH)D level and as
Vitamin D and HIV Progression for Adults on ART
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e40036a result we analyzed 25(OH)D levels categorically with clinical cut-
offs as well as continuously [29,30]. We defined vitamin D
deficiency as 25(OH)D concentrations ,20 ng/mL, insufficiency
20–30 ng/mL, and sufficiency as .30 ng/mL [31–33]. The
possible non-linear relation between serum 25(OH)D and
mortality was also examined non-parametrically with restricted
cubic splines [34,35]. Tests for non-linearity used the likelihood
ratio test, comparing the model with only the linear term to the
model with the linear and the cubic spline terms. Individuals
without events were censored at the date of last follow-up visit.
Confounders considered for multivariate mortality models in-
cluded variables with univariate p-values ,0.20 in the risk factor
analysis or variables noted to be significant confounders in
previous studies were selected for inclusion.
Associations of vitamin D status and CD4 T-cell counts were
analyzed with generalized estimating equations. Change in CD4
T-cell count between consecutive visits was treated as a longitudi-
nal continuous outcome and vitamin D, time since ART initiation,
along with other baseline covariates as explanatory variables. We
used an m-dependent working correlation matrix (m=1) assuming
the correlation coefficient of adjacent observations are non-zero
and equal, and robust estimators of the variances were utilized to
construct confidence intervals. The robust estimators are consis-
tent estimators of the variances even if the working correlation
matrix is misspecified. The potential non-linear relationship of
change in T-cell counts between consecutive visits over time was
examined non-parametrically with restricted cubic splines for time
since ART initiation [34,35]. If a non-linear relationship was
found, we added the selected cubic spline terms to the above-
specified model as covariates. To assess whether vitamin D status
was associated with change in CD4 T-cell between consecutive
visits over time, we included the interactions of vitamin D status
with time since ART initiation and its splines. The robust score
test was used to determine whether vitamin D deficient and
insufficient individuals differed in CD4 T-cell trajectory as
compared to sufficient individuals. Confounders were also selected
from the risk factor analysis; however, baseline CD4 T-cell count
was not adjusted for as it will result in biased estimates [12].
Effect modification by all covariates, randomized multivitamin
regimen, and ART regimen were considered for all analyses.
Interaction by ART regimen was examined for each of the four
regimen combinations and also by antiretroviral drug (i.e.
efavirenz-containing regimen). To determine whether effect
modification was statistically significant, we used the likelihood
ratio test in proportional hazard models and the robust score test
in GEE analyses. Missing data for covariates was retained in the
analysis using the missing indicator method for variables missing
greater than 1% of the observations [36]. All p-values were 2-sided
and p,0.05 considered statistically significant. Statistical analyses
were performed using the SAS v 9.2 (SAS Institute Inc., Cary, NC,
USA).
Ethics Statement
Written informed consent was obtained from all participants
included in the parent trial. The trial protocol was approved by the
institutional review boards of the Harvard School of Public
Health, Muhimbili University of Health and Allied Sciences,
Tanzania Food and Drug Authority and National Institute of
Medical Research.
Results
A total of 1103 individuals were randomly selected for 25(OH)D
testing from 3,418 individuals enrolled in the parent trial. There
were no significant differences between the randomly selected
cohort and the trial population. 101 (9.2%) individuals were
classified as vitamin D deficient (,20 25(OH)D ng/mL), 481
(43.6%) as insufficient (20–30 ng/mL), and 521 (47.2%) as vitamin
D sufficient (.30 ng/mL). Baseline characteristics of the cohort at
ART initiation visit are presented in Table 1. A multivariate risk
factor analysis determined low vitamin D (25(OH)D ,30 ng/mL)
was independently associated with younger age (p,0.001),
increased CD4 T-cell count (p,0.001), and season of the ART
initiation visit (Table 2).
The median follow-up time was 20.6 months (IQR: 8.4–33.8),
during which 151 deaths were recorded. A crude Kaplan-Meir
curve for all-cause mortality by vitamin D status is presented in
Figure 1 showing that at 24 months post ART initiation 22.8% of
the individuals with deficient vitamin D levels died as compared to
14.1% and 13.1% of individuals with insufficient and deficient
levels of vitamin D, respectively.
The results of univariate and multivariate proportional hazard
analyses for mortality outcomes by vitamin D status are presented
in Table 3. After multivariate adjustment, the hazard of death was
2.00 (95% CI: 1.19–3.37; p=0.009) times greater for individuals
with vitamin D deficiency at baseline compared to vitamin D
sufficient individuals. There was no significant increase for
individuals with insufficient levels of vitamin D compared to
sufficient individuals (HR: 1.24; 95%: 0.87–1.78; p=0.240).
Further, when analyzing 25(OH)D as a continuous variable we
found a non-linear relationship with increasing risk of all-cause
mortality below 25 ng/mL and seemingly no increased benefit to
baseline vitamin D levels greater than 30 ng/mL (Figure 2). No
significant effect modification by baseline CD4 T-cell count, age,
sex, randomized multivitamin regimen, ART regimen or specific
antiretroviral drug was found. There was also no indication that
the hazard of death for vitamin D deficiency (p=0.97) or
insufficiency (p=0.40) changed over time.
A total of 875 individuals had 2 or more CD4 T-cell count
measurements during the study period. As expected the change in
CD4 T-cell count post ART initiation was non-linear. Partici-
pants, regardless of vitamin D status, experienced dramatic
increases in CD4 T-cell counts during the first 6 months of
ART with more modest gains thereafter (Figure 3). In crude
models adjusting solely for time between visits, the trajectory of
change in CD4 T-cell count between consecutive visits did not
differ in vitamin D deficient (p=0.403) or insufficient (p=0.885)
individuals as compared to those with sufficient vitamin D levels at
baseline. There were no differences in CD4 T-cell trajectory in
multivariate models further adjusting for sex, age, WHO HIV
disease stage, BMI, and ART regimen for deficient (p=0.374) or
insufficient individuals (p=0.943) as compared to sufficient
individuals. No significant effect modification by age, sex,
randomized multivitamin regimen, ART regimen or specific
antiretroviral drug was found.
Discussion
In this study we found individuals with deficient levels of
vitamin D (,20 ng/mL) at ART initiation had significantly
increased risk of mortality as compared to individuals with
sufficient levels of vitamin D (.30 ng/mL), whereas there was no
significant increase for individuals with vitamin D insufficiency
(20–30 ng/mL). The benefit of sufficient vitamin D does not
appear to be mediated through improved immune reconstitution
as there was no association between vitamin D status and change
in CD4 T-cell count after ART initiation. We also found no effect
Vitamin D and HIV Progression for Adults on ART
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mortality or CD4 T-cell analyses.
The mortality results of this study are consistent with previous
cohort studies. In the EUROSIDA study adults in the lowest tertile
of 25(OH)D (,12 ng/mL) had significantly increased incidence of
mortality as compared adults in the middle (12.1–20 ng/mL) and
highest tertile ($20 ng/mL), but there was no significant difference
between the middle and highest tertiles [21]. Individuals in the
EUROSIDAcohorthadmarkedlylowlevelsofvitaminDwith89%
of individuals below 30 ng/mL and as a result, the study likely had
inadequate power to examine the relationship using clinical
classifications with sufficiency (.30 ng/mL) defining the referent
group. The second cohort study consisting of Tanzanian pregnant
women did not find a significant association of low vitamin D with
all-cause mortality using a cut-off of 32 ng/mL, but found
a significant difference when comparing women in the lowest
quintile of vitamin D to the highest quintile [16]. As opposed to the
EUROSIDA study, these Tanzanian pregnant women may have
had too high levels of vitamin D to find a significant difference with
these clinical cutoffs since only 40% of women had levels below
32 ng/mLwithveryfewbelow20 ng/mL.Ourcategoricalanalyses
in this study found individuals with vitamin D deficiency (,20 ng/
mL) had significantly increased risk of mortality as compared to
those with sufficient vitamin D levels ($30 ng/mL), while individ-
uals with vitamin D insufficiency (20–30 ng/mL) appeared to have
more moderately elevated mortality risk, but results were not
statistically significant. Nevertheless, our analysis of 25(OH)D as
a continuous exposure suggests mortality risk begins to increase at
levels below 25 ng/mL. Accordingly, using the standard vitamin D
status classifications (,20, 20–30, $30 ng/mL) may make cross
Table 1. Characteristics of Vitamin D cohort at baseline ART Initiation visit by vitamin D status.
Vitamin D Deficient
,20 ng/mL (n=101)
Vitamin D Insufficient
20–30 ng/mL (n=481)
Vitamin D Sufficient
.30 ng/mL (n=521)
Mean 6 SD or Frequency (%) Mean 6 SD or Frequency (%) Mean 6 SD or Frequency (%)
Female 372 (71.3) 336 (69.9) 351 (67.4)
Age (years)
Under 30 18 (17.8) 85 (17.7) 58 (11.1)
30–40 56 (55.4) 241 (50.1) 249 (47.8)
40–50 17 (16.8) 110 (22.9) 167 (32.1)
Over 50 10 (9.9) 45 (9.4) 47 (9.0)
Season
Long Rain (Dec-Mar) 9 (8.9) 58 (12.1) 83 (15.9)
Harvest (Apr-May) 10 (9.9) 48 (10.0) 92 (17.7)
Post Harvest (Jun-Aug) 61 (60.4) 224 (46.6) 173 (33.2)
Short Rain (Sept-Nov) 21 (20.8) 151 (31.4) 173 (33.2)
BMI (kg/m
2)
Severe underweight (,16.0) 10 (10.1) 22 (4.6) 41 (7.9)
Underweight (16.0–18.5) 24 (24.2) 95 (19.9) 111 (21.5)
Normal (18.5–25) (ref) 49 (49.5) 286 (59.8) 302 (58.5)
Overweight (.25.0) 16 (16.2) 75 (15.7) 62 (12.0)
WHO HIV Disease Stage
I or II 24 (25.8) 111 (25.4) 100 (21.1)
III 51 (54.8) 274 (62.7) 306 (64.5)
IV 18 (19.4) 52 (11.9) 68 (14.3)
CD4 T-cell Category (cells/ mL)
,50 15 (15.0) 76 (16.7) 123 (24.5)
50–100 12 (12.0) 72 (15.8) 113 (22.5)
100–200 49 (49.0) 200 (43.9) 180 (35.7)
.200 24 (24.0) 108 (23.7) 87 (17.3)
Hemoglobin (g/dL) 9.9962.34 10.2562.26 10.0562.23
ART regimen prescribed at baseline*
d4T, 3TC, NVP 52 (51.5) 278 (57.8) 299 (57.4)
d4T, 3TC, EFV 11 (10.9) 49 (10.2) 58 (11.1)
AZT, 3TC, NVP 6 (5.9) 39 (8.1) 43 (8.3)
AZT, 3TC, EFV 32 (31.7) 115 (23.9) 121 (23.2)
Vitamin D (ng/mL) 16.463.15 25.3362.77 36.9766.22
d4T=stavudine, AZT=zidovudine, 3TC=lamivudine, NVP=nevirapine, EFV=efavirenz.
*Vitamin D levels obtained before ART initiation.
doi:10.1371/journal.pone.0040036.t001
Vitamin D and HIV Progression for Adults on ART
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e40036study comparison less complicated; however, more research with
synthesisofresultsindifferentsettingsisneededtodetermineifthese
standard cut-offs based on calcium homeostasis and parathyroid
hormone (PTH) regulation are directly applicable to the vitamin D
and HIV mortality relationship, especially for individuals inthe 20–
30 ng/mL 25(OH)D range [29,31–33].
The beneficial effect of vitamin D on mortality for HIV-infected
individuals may be partially explained by its regulatory effect on
the innate immune system [37,38]. Recent studies have found
vitamin D is required for proper functioning of an interferon-
gamma mediated pathway in macrophages which leads to
autophagy, phagosomal maturation, and antimicrobial activity
[5,6]. Expression of antimicrobial peptides, including cathelicidin
and defensin b2, are also up-regulated in macrophages stimulated
by 1,25(OH)2D, however if 1,25(OH)2D levels fall below 20 ng/
mL the cathelicidin response is not initiated [38–40]. Conse-
quently, individuals with vitamin D deficiency may have impaired
innate immune responses which result in increased incidence or
more severe opportunistic infections.
As for adaptive immune responses, 1,25(OH)2D has been shown
to reduce T-cell proliferation due to suppression of interleukin
(IL)-2 and direct inhibition of NFATp/AP-1 formation in vitro
[41,42]. Consistent with these findings we found that sufficient
levels of vitamin D were associated with lower CD4 T-cell counts
at baseline, but there was no difference in CD4 T-cell count
change over time after ART initiation by vitamin D status. In
contrast, previous cross-sectional studies have found low vitamin D
levels were associated with low CD4 T-cell counts, which is also
biologically plausible since individuals with low CD4 T-cell counts
have decreased exposure to sunlight or increased risk of
opportunistic infections that may lead to increased immune
activation and utilization of vitamin D by immune cells [43–46]. A
possible explanation for these seemingly conflicting results is that
the 25(OH)D and CD4 T-cell relationship takes on a U-shaped
curve. Cross-sectional studies that have found an association of low
vitamin D and low CD4 T-cell count have mainly been conducted
in high latitude settings where very few individuals have 25(OH)D
levels above 30 ng/mL [43–45]. As a result, the reference group in
Table 2. Risk factors for low vitamin D (,30 ng/mL).
Univariate RR (95% CI) p-value* Multivariate RR (95% CI) p-value*
Sex
Female (ref) 1.0 1.0
Male 0.94 (0.83–1.06) 0.334 1.00 (0.88–1.14) 0.992
Age (years)
Under 30 (ref) 1.0 0.002 1.0 ,0.001
30–40 0.85 (0.74–0.98) 0.85 (0.75–0.98)
40–50 0.68 (0.57–0.80) 0.66 (0.56–0.79)
Over 50 0.84 (0.68–1.04) 0.79 (0.64–0.98)
Season
Long Rain (Dec-Mar) 0.72 (0.59–0.87) ,0.001 0.77 (0.63–0.92) 0.005
Harvest (Apr–May) 0.62 (0.50–0.77) ,0.001 0.62 (0.50–0.76) ,0.001
Post Harvest (Jun–Aug) (ref) 1.0 1.0
Short Rain (Sept–Oct) 0.80 (0.71–0.91) ,0.001 0.80 (0.71–0.91) 0.001
BMI (kg/m
2)
Severely underweight (,16.0) 0.74 (0.55–0.99) 0.030 0.78 (0.58–1.05) 0.091
Underweight (16.0–18.5) 0.87 (0.73–1.04) 0.90 (0.58–1.08)
Normal (18.5–25) 0.88 (0.76–1.03) 0.90 (0.77–1.04)
Overweight (.=25.0) (ref) 1.0 1.0
WHO HIV Disease Stage
I or II 1.13 (0.93–1.38) 0.132 1.04 (0.85–1.28) 0.564
III 1.02 (0.84–1.22) 0.98 (0.82–1.17)
IV (ref) 1.0 1.0
CD4 T-cell count (cells/ mL)
,50 0.71 (0.58–0.85) ,0.001 0.69 (0.57–0.83) ,0.001
50–100 0.71 (0.69–0.86) 0.70 (0.58–0.85)
100–200 0.96 (0.84–1.10) 0.92 (0.71–1.20)
.200 (ref) 1.0 1.0
Hemoglobin (g/dL)
,8.5 0.92 (0.79–1.09) 0.368 0.95 (0.73–1.22) 0.512
8.5–10.9 0.96 (0.84–1.09) 1.02 (0.87–1.21)
,=11 (ref) 1.0 1.0
*p-value for test for trend for rank variables.
doi:10.1371/journal.pone.0040036.t002
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levels to experience a pronounced reduction in CD4 T-cell
proliferation, whereas in our study about 50% of individuals have
25(OH)D levels above 30 ng/mL the reference group may have
25(OH)D levels where CD4 T-cell proliferation is significantly
inhibited.
In longitudinal analyses we found no association between
vitamin D and change in CD4 T-cell counts after ART initiation.
These results are consistent with a previous observational cohort
study of German adults primarily receiving ART which found no
difference in median CD4 T-cell recovery rates during follow-up
for the total cohort or when stratified by baseline CD4 T-cell
count [47]. In contrast, a cohort study of US adults receiving ART
Figure 1. Kaplan-Meier estimation of progression to all-cause mortality by vitamin D status.
doi:10.1371/journal.pone.0040036.g001
Table 3. Hazard ratio for mortality by vitamin D status.
Vitamin D Deficient
(,20 ng/mL) p-value
Vitamin D Insufficient
(20–30 ng/mL) p-value
Vitamin D Sufficient
(.30 ng/mL)
Unadjusted All-Cause Mortality
(n=151)
1.83 (1.12–3.30) 0.016 1.09 (0.77–1.53) 0.633 1.0 (ref)
Adjusted* All-Cause Mortality
(n=151)
2.00 (1.19–3.37) 0.009 1.24 (0.87–1.78) 0.240 1.0 (ref)
*Adjusted for baseline sex, age, season, BMI, WHO HIV disease stage, and CD4 T-cell count.
doi:10.1371/journal.pone.0040036.t003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e40036Figure 2. Restricted cubic spline analysis illustrating the shape of the serum 25(OH)D and all-cause mortality association (hazard
ratio) continuously with 30 ng/mL as the referent level. Adjusted for baseline sex, age, season, BMI, WHO HIV disease stage, and CD4 T-cell
count.
doi:10.1371/journal.pone.0040036.g002
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change in CD4 T-cell count (current minus nadir) overtime [48].
Nevertheless, the authors adjusted for nadir CD4 T-cell count in
analyses, which can produce bias if vitamin D is associated with
baseline health status and also vitamin D was measured at least 24
weeks after start of ART which increases the risk of reverse
causation [49]. Further, two small randomized controlled trials in
HIV-infected children on ART also reported no effect of vitamin
D supplementation on change in CD4 T-cell count overtime
[50,51]. Overall, our risk factor analysis and other cross-sectional
studies have produced varying results for the impact of vitamin D
on CD4 T-cell count, but our prospective analysis along with other
longitudinal studies and randomized trials suggest there is no
pronounced difference in change in CD4 T-cell counts during the
initial months of ART by vitamin D status.
Figure 3. Crude CD4 T-cell count overtime by vitamin D status.
doi:10.1371/journal.pone.0040036.g003
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sufficient vitamin D for other aspects of adaptive immune
responses. In addition to IL-2 suppression, vitamin D also reduces
production of other proinflammatory Th1 and Th17 cytokines,
while also enhancing production of Th2 promoting cytokines
including: IL-4, IL-5, and IL-10 [52–55]. 1,25(OH)2D has also
been shown to reduce B-cell proliferation, plasma differentiation,
and immunoglobulin production in vitro [56,57]. Further, 1,
25(OH)2D can also suppress the response of Th17 cells, which
cause inflammation and tissue destruction and also induce Foxp3+
T regulatory cells, which suppress excessively strong CD4 T-cell
proliferation [58,59]. The sum of these actions will likely decrease
inflammation, tissue damage, and reduce excessively strong
immune responses to opportunistic infections in individuals with
adequate levels of vitamin D which may in turn lead to reduced
mortality [60,61]. Overall, there are multiple mechanisms by
which vitamin D may support innate or adaptive immune
responses to opportunistic infections and reduce subsequent
mortality.
Antiretroviral drugs can alter vitamin D metabolism and result
in decreased circulating 25(OH)D [19]. The non-nucleoside
reverse transcriptase inhibitor (NNRTI) efavirenz induces 24-
hydroxylase, which hydrolyzes active vitamin D to its inactive
form [62]. A prospective study of individuals initiating ART in the
US found individuals receiving regimens containing efavirenz had
1.8 times the risk of developing 25(OH)D levels #15 ng/mL as
compared to individuals initiating regimens containing protease
inhibitors [63]. Further, the Monet trial found that patients who
switched from regimens containing efavirenz and/or zidovudine
to darunavir/ritonavir experienced increases in serum 25(OH)D
[64]. Protease inhibitors have also been noted to alter vitamin D
metabolism, but we were unable to investigate this class of
antiretroviral drugs as they were not used in Tanzania during the
study period [65,66]. We did not find effect modification of
mortality or CD4 T-cell associations by efavirenz-containing or
other ART regimens in this analysis. However, we may have had
limited statistical power to detect multiplicative interaction, and it
is plausible that vitamin D insufficient individuals who decrease
serum 25(OH)D to deficient levels as a result of ART or use of
particular antiretroviral drugs may experience slightly increased
mortality relative to those on ART therapy who maintain
sufficient serum 25(OH)D levels.
A major strength of this study is the use of clinically defined
vitamin D cut-offs, which can make direct comparison of studies
easier. We also quantified 25(OH)D with HPLC-MS/MS,
a reference method, which will reduce non-differential mis-
classification of vitamin D status or even bias if individuals with
more severe HIV disease produce metabolites or other molecules
which may interfere with 25(OH)D measurement using radio-
immunoassy (RIA) [15,67] Furthermore, measuring 25(OH)D at
ART initiation allows for examination of effect modification by
ART regimen. It is unlikely interaction would be detected in
individuals already receiving ARTs at the time of vitamin D
measurement, since individuals would have already experienced
a reduction in circulating 25(OH)D as a result of treatment.
The study also has several important limitations. First, 25(OH)D
was measured at a single time point and we are unable to
determine whether deficient vitamin D levels at a single time point
or long term deficiency is biologically relevant. Nevertheless, we
found no change in the association of vitamin D deficiency at
baseline and mortality over time, which suggests a single vitamin
D measurement at ART initiation may be able to indicate which
patients may benefit from vitamin D supplementation. Second, the
results of this study may not be directly generalizable to other
HIV-infected populations, including pregnant women or children
on ART. A previous study in HIV-infected pregnant women not
receiving ART in Tanzania found having vitamin D levels above
32 ng/mL provided additional benefit; however, this study
indicated no benefit to having levels above 30 ng/mL for men
and non-pregnant women on ART in the same setting [17].
Further, we presented an observational study from which reverse
causation cannot be ruled out as advanced HIV disease or other
co-morbidities may have led to lower vitamin D levels. We
controlled multivariate analyses for multiple indicators of disease
severity (CD4 T-cell count, WHO HIV disease stage, BMI) and if
residual confounding by these factors is present we may actually
underestimate the association of vitamin D and mortality.
Nevertheless, unmeasured confounding by other factors like
tuberculosis or hepatitis C infection at baseline may still produce
biased results [68,69].
This study suggests that deficient vitamin D levels may lead to
increased mortality in HIV-infected men and non-pregnant
women receiving ART and this association does not appear to
be mediated by impaired CD4 T-cell reconstitution. However, due
to the observational design of this study a causal relationship
cannot be concluded. Accordingly, randomized controlled trials
are warranted to determine the safety and efficacy of vitamin D
supplementation for HIV-infected individuals receiving ART.
Acknowledgments
We thank the study participants, and field teams, including physicians,
nurses, midwives, supervisors, laboratory, and the administrative staff, who
made the study possible; and Muhimbili National Hospital, Muhimbili
University of Health and Allied Sciences, City of Dar es Salaam Regional
Office of Health and the National AIDS Control Program/Ministry of
Health and Social Welfare for their institutional support.
Author Contributions
Conceived and designed the experiments: SA FM WWF. Analyzed the
data: CRS MW. Wrote the paper: CRS MW SA ELG FMM WWF.
Developed the data analysis plan: CRS MW ELG WWF.
References
1. Global HIV/AIDS Response (2011) Epidemic update and health sector progress
towards Universal Access. Available: www.who.int/hiv/pub/progress_
report2011/en/index.html. Accessed 2012 Feb 3.
2. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006)
Mortality of HIV-1 infected patients in the first year of antiretroviral therapy:
comparison between low-income and high-income countries. Lancet 367: 817–
824.
3. Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy
programs in resource-poor settings: a meta-analysis of the published literature.
Clin Infect Dis 41: 217–224.
4. Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology.
FASEB J 15: 2579–2585.
5. Kamen DL, Tangpricha V (2010) Vitamin D and molecular actions on the
immune system: modulation of innate and autoimmunity. J Mol Med 88: 441–
450.
6. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, et al. (2011) Vitamin D Is
Required for IFN-{gamma}-Mediated Antimicrobial Activity of Human
Macrophages. Sci Transl Med 3: 104ra102.
7. Yang S, Smith C, Prahl JM, Luo X, DeLuca HF (1993) Vitamin D deficiency
suppresses cell-mediated immunity in vivo. Arch Biochem Biophys 303: 98–106.
8. Bar-Shavit Z, Noff D, Edelstein S, Meyer M, Shibolet S, et al. (1981) 1, 25-
dihydroxyvitamin D3 and the regulation of macrophage function. Calcif Tissue
Int 33: 673–676.
9. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, et al. (2004) Cutting
edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide
gene expression. J Immunol 173: 2909–2912.
Vitamin D and HIV Progression for Adults on ART
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e4003610. Villamor E (2006) A potential role for vitamin D on HIV infection? Nutr Rev 64:
226–233.
11. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2008)
Association of activated vitamin D treatment and mortality in chronic kidney
disease. Arch Intern Med 168: 397–403.
12. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, et al. (2010)
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity
and cancer: recommendations for clinical practice. Autoimmunity Rev 9: 709–
715.
13. Vescini F, Cozzi-Lepri A, Borderi M, Re MC, Maggiolo F, et al. (2011)
Prevalence of hypovitaminosis D and factors associated with vitamin D
deficiency and morbidity among HIV-infected patients enrolled in a large
Italian cohort. J Acquir Immune Defic Syndr 58: 163–72.
14. Haug C, Muller F, Aukrust P, Froland SS (1994) Subnormal serum
concentration of 1,25-vitamin D in human immunodeficiency virus infection:
correlation with degree of immune deficiency and survival. J Infect Dis 169:
889–893.
15. Holick MF. (2009) Vitamin D status: measurement, interpretation, and clinical
application. Ann Epidemiol 19: 73–8.
16. Mehta S, Giovanucci E, Mugusi FM, Spiegelman D, Aboud S, et al. (2010)
Vitamin D status of HIV-infected women and its association with HIV disease
progression, anemia, and mortality. PLoS One 5: e8770.
17. Mehta S, Hunter DJ, Mugusi FM, Spiegelman D, Manji KP, et al. (2009)
Perinatal outcomes, including mother-to-child transmission of HIV, and child
mortality and their association with maternal vitamin D status in Tanzania.
J Infect Dis 200: 1022–1030.
18. Mehta S, Mugusi FM, Spiegelman D, Villamor E, Finkelstein JL, et al. (2011)
Vitamin D status and its association with morbidity including wasting and
opportunistic illnesses in HIV-infected women in Tanzania. AIDS Patient Care
STDS 25: 579–85.
19. Yin M, Stein E (2011) The effect of antiretrovirals on vitamin D. Clin Infect Dis
52: 406–8.
20. Brannon PM, Picciano MF (2011) Vitamin D in pregnancy and lactation in
humans. Annu Rev Nutr 21: 31: 89–115.
21. Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, et al. (2011) Vitamin D
and clinical disease progression in HIV infection: results from the EuroSIDA
study. AIDS 25: 1305–15.
22. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006)
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:
comparison between low-income and high-income countries. Lancet 367: 817–
24.
23. World Health Organization (2004) Scaling up antiretroviral therapy in resource-
limited settings: treatment guidelines for a public health approach. Geneva:
World Health Organization.
24. Lensmeyer GL, Wiebe DA, Binkley N, Drezner MK (2006) HPLC method for
25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin
Chem 52: 1120–6.
25. Wacholder S (1986) Binomial regression in GLIM: Estimating risk ratios and risk
differences. Am J Epidemiol 123: 174–184.
26. Spiegelman D, Hertzmark E (2005) Easy SAS calculations for risk or prevalence
ratios and differences. Am J Epidemiol 162, 199–200.
27. Zou G (2004) A modified Poisson regression approach to prospective studies
with binary data. Am J Epidemiol 159: 702–706.
28. Cox D (1972) Regression models and life tables. J Royal Stat Soc 34: 187–220.
29. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes
B (2006) Estimation of optimal serum concentrations of 25- hydroxyvitamin D
for multiple health outcomes. Am J Clin Nutr 84: 18–28.
30. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281.
31. Heaney RP (2004) Functional indices of vitamin D status and ramifications of
vitamin D deficiency. Am J Clin Nutr 80: 1706S–1709S.
32. Institute of Medicin (2011) Dietary Reference Intakes for Calcium and Vitamin
D. Washington, DC: The National Academies Press.
33. Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Engelke JA, et al. (2008)
Vitamin D insufficiency: disease or no disease? J Bone Miner Res 23: 1052–
1060.
34. Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat
Med 8: 551–561.
35. Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA (2007)
Comparing smoothing techniques in Cox models for exposure-response
relationships. Stat Med 26: 3735–52.
36. Miettinen O (1985) Theoretical Epidemiology. New York: John Wiley & Sons.
37. Mora JR, Iwata M, von Andrian UH (2008) Vitamin effects on the immune
system; vitamins A and D take centre stage. Nature Rev Immunol 8: 685–698.
38. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. (2006) Toll-like receptor
triggering of a vitamin D-mediated human antimicrobial response. Science 311:
1773–3.
39. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, et al. (2004) Cutting
edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide
gene expression. J Immunol 173: 2909–2912.
40. Gombart AF, Borregaard N, Koeffler HP (2005) Human cathelicidin
antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor
and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3.
FASEB J 19: 1067–1077.
41. Rigby WF, Stacy T, Fanger MW (1984) Inhibition of T lymphocyte mitogenesis
by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 74: 1451–1455.
42. Alroy I, Towers TL, Freedman LP (1995) Transcriptional repression of the
interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex
formation by a nuclear hormone receptor. Mol Cell Biol 15: 5789–5799.
43. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, et al. (2010) Efavirenz is
associated with severe vitamin D deficiency and increased alkaline phosphatase.
AIDS 24: 1923–8.
44. Stein EM, Yin MT, McMahon DJ, Shu A, Zhang CA, et al. (2011) Vitamin D
deficiency in HIV-infected postmenopausal Hispanic and African-American
women. Osteoporos Int. 22: 477–87.
45. Haug CJ, Aukrust P, Haug E, Mørkrid L, Mu ¨ller F, et al. (1998) Severe
deficiency of 1,25- dihydroxyvitamin D3 in human immunodeficiency virus
infection: Association with immunological hyperactivity and only minor changes
in calcium homeostasis. J Clin Endocrinol Metab 83: 3832–3838.
46. Martineau AR (2012) Old wine in new bottles: vitamin D in the treatment and
prevention of tuberculosis. Proc Nutr Soc 71: 84–9.
47. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus
AR, et al. (2008) Vitamin D deficiency among HIV type 1-infected individuals in
the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses
24: 1375–82.
48. Ross AC, Judd S, Kumari M, Hileman C, Storer N, et al. (2011) Vitamin D is
linked to carotid intima-media thickness and immune reconstitution in HIV-
positive individuals. Antivir Ther 16 : 555–63.
49. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM (2005) When is
baseline adjustment useful in analyses of change? An example with education
and cognitive change. Am J Epidemiol 162: 267–78.
50. Arpadi SM, McMahon D, Abrams EJ, Bamji M, Purswani M, et al. (2009) Effect
of bimonthly supplementation with oral cholecalciferol on serum 25-hydro-
xyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics
121–126.
51. Kakalia S, Sochett EB, Stephens D, Assor E, Read SE, et al. (2011) Vitamin D
Supplementation and CD4 Count in Children Infected with Human
Immunodeficiency Virus. J Pediatr 159: 951–947.
52. Overbergh L, Decallonne B, Waer M, Rutgeerts O, Valckx D, et al. (2000) 1
alpha, 25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-
helper 2 immune shift in NOD mice immunized with GAD65. Diabetes 49:
1301–1307.
53. Bhalla AK, Amento EP, Serog B, Glimcher LH (1984) 1, 25- Dihydroxyvitamin
D3 inhibits antigen-induced T cell activation. J Immunol 133: 1748–1754.
54. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, et al. (2001) A1alpha,
25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance
the development of Th2 cells. J Immunol 169: 4974–4980.
55. Tang J, Zhou R, Luger D, Zhu W, Silver PB, et al. (2009) Calcitriol suppresses
antiretinal autoimmunity through inhibitory effects on the Th17 effector
response. J Immunol 182: 4624–4632.
56. Lemire JM, Adams JS, Sakai R, Jordan SC (1984) 1 alpha, 25- dihydroxyvitamin
D3 suppresses proliferation and immunoglobulin production by normal human
peripheral blood mononuclear cells. J Clin Invest 74: 657–661.
57. Chen S, Sims GP, Chen XX, Gu YY, Chen S, et al. (2007) Modulatory effects of
1, 25 dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:
1634–47.
58. Tang J, Zhou R, Luger D, Zhu W, Silver PB, Grajewski RS, et al. (2009)
Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the
Th17 effector response. J Immunol 182: 4624–4632.
59. Gorman S, Kuritzky LA, Judge MA, Dixon KM, McGlade JP, et al. (2007)
Topically applied 1, 25-dihydroxyvitamin D3 enhances the suppressive activity
of CD4+ CD25+ cells in the draining lymph nodes. J Immunol 179: 6273–6283.
60. Deeks SG (2009) Immune dysfunction, inflammation, and accelerated aging in
patients on antiretroviral therapy. Top HIV Med 17: 118–23.
61. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008)
Inflammatory and coagulation biomarkers and mortality in patients with HIV
infection. PLoS Med 5: e203.
62. Overton ET, Yin MT (2011) The Rapidly Evolving Research on Vitamin D
Among HIV-Infected Populations. Curr Infect Dis Rep 13: 83–93.
63. Brown TT, McComsey GA (2010) Association between initiation of antire-
troviral therapy with efavirenz and decreases in 25- hydroxyvitamin D. Antivir
Ther 15: 425–429.
64. Fox J, Peters B, Prakash M, Arribas J, Hill A, et al. (2011) Improvement in
vitamin D deficiency following antiretroviral regime change: results from the
MONET trial. AIDS Res Hum Retroviruses 27: 29–34.
65. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, et al. (2003)
HIV protease inhibitors impair vitamin D bioactivation to 1,25- dihydrox-
yvitamin D. AIDS 17: 513–520.
66. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, et al. (2011) Low vitamin D
among HIV-infected adults: prevalence of and risk factors for low vitamin D
Levels in a cohort of HIV-infected adults and comparison to prevalence among
adults in the US general population. Clin Infect Dis 52: 396–405.
67. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, et al. (2011) The
2011 report on dietary reference intakes for calcium and vitamin D form the
Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:
53–58.
Vitamin D and HIV Progression for Adults on ART
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e4003668. Terrier B, Carrat F, Geri G, Pol S, Piroth L, et al. (2011) Low 25-OH vitamin D
serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with
chronic hepatitis. J Hepatol 55: 756–61.
69. Realegeno S, Modlin RL (2011) Shedding light on the vitamin D-tuberculosis-
HIV connection. Proc Natl Acad Sci USA 108: 18861–2.
Vitamin D and HIV Progression for Adults on ART
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e40036